Viatris global portfolio comprises more than 1,400 molecules across a broad range of major therapeutic areas, including best-in-class, iconic brand-name products, as well as global key brands, generics, including branded and complex generics, biosimilars and over-the-counter offerings.

From cardiovascular health to oncology, we offer quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases. We also offer beyond the medicine solutions and services such as diagnostics, health literacy support and digital tools to help patients better manage their health. We consider it our duty to advocate for policies that advance knowledge and education, reduce barriers to treatment access to achieve better health for patients and unlock value for health systems.

Our diverse and differentiated portfolio, supported by world-class commercial and regulatory expertise, delivers trusted, quality medicines that treat nine out of 10 of the World Health Organization’s (WHO) leading causes of death and more than 200 of our medicines are on the WHO Essential Medicines List.

Upjohn Portfolio

Mylan portfolio